FIGURE 2.

Actionability across pharmacogenes meeting Clinical Pharmacogenetics Implementation Consortium (CPIC) level A or B evidence threshold. Red squares indicate the overall prevalence of actionable genotypes in the cohort. ABCG2 actionability is based on homozygosity for the major allele. For G6PD, actionability was defined as men with one variant allele and women with two variant alleles. No participants had variation in MT‐RNR1, and no participants of African ancestry had an actionable NUDT15 genotype. CYP2D6 was not adequately interrogated on the array, and only a limited number of actionable genotypes could be determined. The actionable variant for SLC6A4 was not available